Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan List

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
International Journal of Hematology|March 15, 2006
Myelodysplastic syndromeShinji Nakao, H Joachim Deeg, Takayuki Ishikawa, et al.
Annals of Hematology|September 11, 2013
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Leukemia Research|March 2, 2016
T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significanceXiaohui Zhang, Lubomir Sokol, John M Bennett, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before AzacitidineAmer M Zeidan, Najla H Al Ali, Eric Padron, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic SyndromeMintallah Haider, Najla Al Ali, Eric Padron, et al.
American Journal of Hematology|March 25, 2015
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesJason Brayer, Jeffrey E Lancet, John Powers, et al.
Cancer|March 17, 2007
The incidence and impact of thrombocytopenia in myelodysplastic syndromesHagop Kantarjian, Francis Giles, Alan List, et al.
Journal of the National Cancer Institute|October 30, 2008
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveysMikkael A Sekeres, W Marieke Schoonen, Hagop Kantarjian, et al.
Molecular Cancer Therapeutics|April 14, 2007
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cellsSangkil Nam, Ann Williams, Adina Vultur, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic SyndromeRami Komrokji, Hanadi Ramadan, Najla Al Ali, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
International Journal of Hematology|March 15, 2006
Myelodysplastic syndromeShinji Nakao, H Joachim Deeg, Takayuki Ishikawa, et al.
Annals of Hematology|September 11, 2013
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomesAristoteles Giagounidis, Ghulam J Mufti, Pierre Fenaux, et al.
Leukemia Research|March 2, 2016
T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significanceXiaohui Zhang, Lubomir Sokol, John M Bennett, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 7, 2015
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before AzacitidineAmer M Zeidan, Najla H Al Ali, Eric Padron, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic SyndromeMintallah Haider, Najla Al Ali, Eric Padron, et al.
American Journal of Hematology|March 25, 2015
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesJason Brayer, Jeffrey E Lancet, John Powers, et al.
Cancer|March 17, 2007
The incidence and impact of thrombocytopenia in myelodysplastic syndromesHagop Kantarjian, Francis Giles, Alan List, et al.
Journal of the National Cancer Institute|October 30, 2008
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveysMikkael A Sekeres, W Marieke Schoonen, Hagop Kantarjian, et al.
Molecular Cancer Therapeutics|April 14, 2007
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cellsSangkil Nam, Ann Williams, Adina Vultur, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2015
Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic SyndromeRami Komrokji, Hanadi Ramadan, Najla Al Ali, et al.
Pageof 8